U.S. NASAL SPRAY MARKET ANALYSIS

U.S. Nasal Spray Market Size and Trends

U.S. nasal spray market is estimated to be valued at USD 10.42 Bn in 2024 and is expected to reach USD 16.65 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.9% from 2024 to 2031.

Discover market dynamics shaping the industry request sample copy

The U.S. nasal spray market has witnessed steady growth owing to rising prevalence of allergic rhinitis and nasal congestion. There has been rising demand for nasal sprays over the forecast period due to growing preference for over-the-counter medications and increasing penetration of generic drugs. Self-administration of nasal sprays has made them very convenient to treat various nasal conditions without medical oversight, thus, boosting its adoption. With pharmacological advancements leading to availability of multidose nasal spray formulations with fewer side effects, specialty drugs are likely to dominate the category and fuel competition in the in the near future.

Market Driver – Rising Prevalence of Allergic Rhinitis

With changing environmental conditions and lifestyle patterns, the incidence of allergic rhinitis has increased substantially over the past few decades. Commonly known as hay fever, allergic rhinitis causes symptoms such as sneezing, nasal congestion and nasal irritation. It is one of the most prevalent chronic respiratory diseases worldwide. For instance, according to Medscape, the prevalence of allergic rhinitis in the U.S. was 7.7% in 2022. Rising prevalence of allergic rhinitis can be attributed to increased exposure to indoor and outdoor allergens such as dust mites, animal dander, and pollen grains. Widespread use of air conditioning has led to dry indoor conditions conducive for dust mite growth. The people in the U.S. are now spending more time outdoors involved in activities such as gardening, hiking, camping, and others, thus, exposing themselves to various types of pollen. Changes in lifestyle and diet have also weakened immunity, leading to increased susceptibility. With such a large patient base suffering from bothersome symptoms throughout the year, the demand for effective nasal spray medications for quick relief is growing steadily.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Get instant access to report

Increased diagnosis of allergic rhinitis and other similar conditions in the U.S. and greater awareness about nasal allergies among both patients and physicians has changed the treatment seeking behavior. People no longer consider symptoms such as sneezing or nasal congestion as a minor irritant but rather seek medical advice to get an accurate diagnosis and appropriate treatment. This is due to intense medical marketing by pharmaceutical companies and as patients now understand that leaving the condition untreated can affect their quality of life and productivity. Once diagnosed, the majority of the people prefer easy to use nasal spray medications over oral antihistamines due to the faster onset of action and topical delivery of drug. 

To learn more about this report, request sample copy

Oral medications remain a cost-effective alternative for many conditions typically treated with nasal sprays. Furthermore, the rise of advanced inhalers provides stiff competition in respiratory applications such as allergies and asthma. Manufacturers must clearly demonstrate the clinical advantages of nasal sprays to justify their higher costs. Another challenge is the lack of insurance coverage for some new nasal spray products, which can limit market potential.

Market Opportunities – Increased Research and Development on Combination Therapies

The U.S. nasal spray market has immense scope for growth through increased focus on combination therapies. Most nasal spray products are targeted towards individual conditions like congestion, allergies or dryness. However, nasal issues often occur concurrently requiring treatment of multiple symptoms. Combination therapies present a huge opportunity to address this clinical need comprehensively. Nasal sprays containing more than one active ingredient can provide relief from multiple bothersome nasal problems with just one product. This improves patient convenience and compliance significantly. For example, a spray treating congestion as well as dryness will eliminate the need to use two different bottles. Combining medications also allows delivering lower doses of each component, reducing risks of side effects.

Discover high revenue pocket segments and roadmap to it: Get instant access to report

Product Type segment is sub-segmented into steroid sprays, antihistamine sprays, decongestant sprays, others. Antihistamine sprays segment is expected to hold 34.7% of the market share in 2024, due to its convenience and efficacy benefits. As a topical treatment delivered directly to the nasal passages, antihistamine sprays provide fast acting, targeted relief from symptoms of allergies like sneezing, itching and congestion. The convenient "spray and go" portable format makes antihistamine sprays ideal for on-the-go use. Their quick absorption into nasal tissues also means antihistamine sprays start working more rapidly than oral antihistamines that must pass through the digestive system first. This faster relief offered by antihistamine sprays address the need of many allergy sufferers for relief as symptoms arise. The localized delivery of antihistamine medication directly where it is needed also minimizes the risk of potential drowsiness side effects associated with some oral antihistamines.

Insights, By Type: Self-care flexibility boosts over-the-counter segment growth

Type segment includes is sub-segmented into prescription and over-the-counter. Over-the-counter segment is expected to hold 57.4% of the market share in 2024, owing to its flexibility and accessibility advantages over prescription medications. Unlike prescription nasal sprays which require a doctor's visit for assessment and continued renewals, over-the-counter sprays empower individuals to easily purchase medications whenever symptoms flare up without a prescription. This self-care flexibility allows over-the-counter users full control over managing mild to moderate allergy and congestion cases, according to their personal needs and schedules. By removing barriers posed by medical appointments and prescription authorizations, over-the-counter availability broadens the potential market reach and makes relief more practical to obtain. Ease of acquisition from retail pharmacy shelves means over-the-counter sprays are not constrained by a prescriber's limited operating hours or prescription coverage limitations.

Insights, By Indication: Increasing Prevalence of Allergic Rhinitis

Indication segment is sub-segmented into allergic rhinitis, nasal allergies, nasal congestion, others. Allergic rhinitis segment is expected to hold 31.2% of the market share in 2024, owing to increasing prevalence of allergic rhinitis. Allergic rhinitis is a condition characterized by inflammation of the nasal passages due to an allergic response. The allergic response is triggered by exposure to allergens such as pollen, dust mites, animal dander, mould, and certain foods. The symptoms of allergic rhinitis include sneezing, itching, runny nose, and nasal congestion. These symptoms can significantly impact a person's quality of life, leading to limitations in daily activities, social behavior, and emotional well-being.

Market Report Scope

U.S. Nasal Spray Industry News

• On February 2, 2024, Lupin, a pharmaceutical company, launched Cyanocobalamin Nasal Spray, 500 mcg/spray in U.S. The Cyanocobalamin Nasal Spray, 500 mcg/spray (One Spray per Device) is a generic equivalent of Nascobal Nasal Spray, 500 mcg/spray of Par Pharmaceutical, Inc., a pharmaceutical company.
• In March 2023, Pfizer, Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved ZAVZPRET (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults
• In August 2022, Hikma Pharmaceuticals PLC, a pharmaceutical company, launched RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the U.S. for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older

*Definition: Nasal sprays are used to locally or systemically provide drugs to the nasal cavities. These are applied locally to treat problems such as allergic rhinitis and nasal congestion. It is marketed as a different, non-invasive route that may be utilized for both local and systemic therapy and is particularly helpful when dealing with medications that are highly metabolized or unstable in the GI (gastrointestinal) medium.

Market Segmentation

• Product Type Insights (Revenue, USD Bn, 2019 - 2031)
• • Steroid Sprays
  • Antihistamine Sprays
  • Decongestant Sprays
  • Others
•  Type Insights (Revenue, USD Bn, 2019 - 2031)
• • Prescription
  • Over-the-Counter
•  Indication Insights (Revenue, USD Bn, 2019 - 2031)
• • Allergic Rhinitis
  • Nasal Allergies
  • Nasal Congestion
  • Others
•  Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Key Players Insights
  • Sanofi
  • GSK plc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca 
  • NeilMed Pharmaceuticals Inc.
  • Neurelis, Inc.
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • GLENMARK PHARMACEUTICALS LTD.
  • Bausch Health Companies Inc. 
  • Viatris Inc.
  • The Procter & Gamble Company 
  • Cipla
  • EMERGENT 
  • Hikma Pharmaceuticals PLC